Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease

Eur J Neurol. 2017 Sep;24(9):1173-1182. doi: 10.1111/ene.13374. Epub 2017 Jul 28.

Abstract

Background and purpose: A growing body of evidence suggests that cardiovascular disease risk factors including hypertension may be linked to sporadic Alzheimer's disease (AD). It is well known that hypertension is associated with cerebrovascular disease and vascular dementia on the basis of vascular remodeling. However, the mechanisms linking hypertension and AD remain unclear.

Methods: We studied 197 patients with AD (86 male; mean age ± SD: 75.8 ± 7.4 years) from the Alzheimer's Disease Neuroimaging Initiative database with (n = 97) and without (n = 100) hypertension. We explored associations between hypertension and clinical, plasma, cerebrospinal fluid and imaging markers of AD pathology in order to elucidate the underlying mechanisms that may link AD and hypertension.

Results: We found that patients with AD with hypertension had worse cognitive function (Alzheimer's disease Assessment Scale-cognitive subscale, P = 0.038) and higher neuropsychiatric symptom burden (Neuropsychiatric Inventory Questionnaire, P = 0.016) compared with those without hypertension. Patients with AD with hypertension showed reduced glucose hypometabolism in the right (P < 0.001) and left (P = 0.007) hippocampus. No differences were found in magnetic resonance imaging volumetric measurements, [18 F]florbetapir uptakes, plasma and cerebrospinal fluid between patients with AD with and without hypertension.

Conclusions: Although hypertension is associated with worse cognitive function, behavioural symptoms and hippocampal glucose hypometabolism, it is not associated with evidence of increased amyloid or tau pathology. Effective management of hypertension may potentially have a therapeutic role in the alleviation of symptoms in AD.

Keywords: Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; blood pressure; hypertension.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / complications*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / psychology*
  • Aniline Compounds / blood
  • Aniline Compounds / cerebrospinal fluid
  • Cognition
  • Cognition Disorders / etiology*
  • Cognition Disorders / metabolism
  • Cognition Disorders / psychology*
  • Cost of Illness
  • Ethylene Glycols / blood
  • Ethylene Glycols / cerebrospinal fluid
  • Female
  • Glucose / metabolism
  • Hippocampus / metabolism*
  • Humans
  • Hypertension / complications*
  • Hypertension / metabolism
  • Hypertension / psychology*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neuroimaging
  • Neuropsychological Tests
  • Positron-Emission Tomography
  • Psychiatric Status Rating Scales
  • Radiopharmaceuticals / blood
  • Radiopharmaceuticals / cerebrospinal fluid

Substances

  • Aniline Compounds
  • Ethylene Glycols
  • Radiopharmaceuticals
  • florbetapir
  • Glucose